Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Poseida Therapeutics stock (PSTX)

Buy Poseida Therapeutics stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Poseida Therapeutics is a biotechnology business based in the US. Poseida Therapeutics shares (PSTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.93 – an increase of 18.62% over the previous week. Poseida Therapeutics employs 337 staff and has a trailing 12-month revenue of around $88.5 million.

Our top picks for where to buy Poseida Therapeutics stock

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

Our pick for transfer bonus

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • Complimentary access to a financial planner and automated investing

How to buy Poseida Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – PSTX. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Poseida Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a no-advisory-fee robo-advisor and complimentary access to financial planners.
Robinhood
Finder Score: 4.5 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Poseida Therapeutics stock price (NASDAQ: PSTX)

Use our graph to track the performance of PSTX stocks over time.

Poseida Therapeutics shares at a glance

Information last updated 2024-11-08.
Latest market close$2.93
52-week range$1.87 - $4.27
50-day moving average $2.75
200-day moving average $2.98
Wall St. target price$14.00
PE ratio N/A
Dividend yield N/A
Earnings per share (TTM) $-1.24

Is it a good time to buy Poseida Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Poseida Therapeutics price performance over time

Historical closes compared with the close of $2.78 from 2024-11-06

1 week (2024-11-01) 12.55%
1 month (2024-10-09) 8.59%
3 months (2024-08-09) -1.77%
6 months (2024-05-09) 2.58%
1 year (2023-11-09) 26.36%
2 years (2022-11-09) -35.50%
3 years (2021-11-09) 6.76
5 years (2019-11-05) N/A

Poseida Therapeutics financials

Revenue TTM $88.5 million
Gross profit TTM $-22,407,000
Return on assets TTM -25.54%
Return on equity TTM -115%
Profit margin -127.48%
Book value $0.63
Market Capitalization $284.6 million

TTM: trailing 12 months

Poseida Therapeutics share dividends

We're not expecting Poseida Therapeutics to pay a dividend over the next 12 months.

Poseida Therapeutics share price volatility

Over the last 12 months, Poseida Therapeutics's shares have ranged in value from as little as $1.87 up to $4.27. A popular way to gauge a stock's volatility is its "beta".

PSTX.US volatility(beta: 0.54)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Poseida Therapeutics's is 0.536. This would suggest that Poseida Therapeutics's shares are less volatile than average (for this exchange).

Poseida Therapeutics overview

Poseida Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc.

Frequently asked questions

What percentage of Poseida Therapeutics is owned by insiders or institutions?
Currently 27.74% of Poseida Therapeutics shares are held by insiders and 55.422% by institutions.
How many people work for Poseida Therapeutics?
Latest data suggests 337 work at Poseida Therapeutics.
When does the fiscal year end for Poseida Therapeutics?
Poseida Therapeutics's fiscal year ends in December.
Where is Poseida Therapeutics based?
Poseida Therapeutics's address is: 9390 Towne Centre Drive, San Diego, CA, United States, 92121
What is Poseida Therapeutics's ISIN number?
Poseida Therapeutics's international securities identification number is: US73730P1084
What is Poseida Therapeutics's CUSIP number?
Poseida Therapeutics's Committee on Uniform Securities Identification Procedures number is: 353539109

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site